Feedback / Questions
cetrelimab (JNJ-63723283) - J&J
tolododekin alfa (ANK-101) - Ankyra Therap
https://www.businesswire.com/news/home/20251117754232/en/Ankyra-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Trial-Evaluating-First-in-Class-Anchored-Immunotherapy-in-Combination-with-Immune-Checkpoint-Blockade-in-Patients-with-Lung-Cancer
Nov 17, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next